Search

Your search keyword '"Frisina, N"' showing total 507 results
Start Over Author "Frisina, N"
507 results on '"Frisina, N"'

12. Effect of stress on the paracellular barrier in the rat ileum. (Small Intestine)

Author

Mazzon, E., Sturniolo, G.C., Puzzolo, D., Frisina, N., and Fries, W.

Subjects
Immunohistochemistry -- Research -- Physiological aspects -- Usage, Intestine, Small -- Physiological aspects -- Usage -- Research, Membrane proteins -- Physiological aspects -- Research -- Usage, Ileum -- Physiological aspects -- Research -- Usage, Rats as laboratory animals -- Physiological aspects -- Usage -- Research, Stress (Psychology) -- Physiological aspects -- Research, Health, Physiological aspects, Usage, Research
Abstract

Background: Restraint stress induces permeability changes in the rat small intestine but little is known of the ultrastructural events leading to defects of the paracellular sealing or of the short [...]

Published
2002

17. The Italian observational study on severe osteoporosis (ISSO): 24-month results on incidence of fractures and adherence to treatment

Author

Window, Trova@UniTO(opens in a. new, Export, Download | Add to List | More,, Rheumatology, Clinical, Experimental, Volume 34, Issue 2, The Italian observational study on severe osteoporosis: 24 month results on incidence of fractures, adherence to treatment Idolazzi, L. Abb, Maugeri, D. B, Monti, S. C, Massarotti, M. D, Osella, G. E, Barbagallo, M. F, Del Fiacco, R. G, Silvestri, S. G, Adami, S. H, Altomonte, L. I, Bardoscia, A. J, Bertoldo, F. K, Bevilacqua, M. L, Bianchi, G. M, Brancati, A. N, Cagnoni, C. O, Cantatore, F. P. P, Capone, A. Q, Costanzo, G. R, D'Avola, G. S, De Giorgi, G. T, Di Matteo, L. U, Di Munno, O. V, Filipponi, P. W, Frisina, N. X, Fusco, A. Y, Giannini, S. Z, Guiducci, S. Aa, Iolascon, G. Ab, Isaia, Giovanni Carlo, Lombardi, G. Ad, Malavolta, N. Ae, Marcocci, C. Af, Migliaccio, S. Ag, Migliore, A. Ah, Muratore, M. Ai, Nardi, A. Aj, Ortolani, S. Ak, Pasquali, R. Al, Petto, H. Am, Pietrogrande, L. An, Pola, E. Ao, Previti, B. Ap, Resmini, G. Aq, Rubinacci, A. Ar, Russo, E. As, Scillitani, A. At, Silveri, F. Au, Leali, P. T. Av, Trotta, F. Aw, Ulivieri, M. Ax, Verdoia, C. Ay, Versace, F. Az, Vinicola, V. Ba, Idolazzi, Luca, Maugeri, Domenico, Monti, Salvatore, Massarotti, Marco, Osella, Giangiacomo, Barbagallo, Mario, Del Fiacco, Romano, Silvestri, Sandra, Adami, S, Altomonte, L, Barbagallo, M, Bardoscia, A, delle Murge, C, Bertoldo, F, Bevilacqua, M, Bianchi, G, Brancati, A, Cagnoni, C, Cantatore, Fp, Capone, A, DI COSTANZO, Gennaro, D'Avola, G, De Giorgi, G, Di Matteo, L, Di Munno, O, Filipponi, P, Frisina, N, Fusco, A, Giannini, S, Guiducci, S, Iolascon, G, Isaia, G, Lombardi, G, Malavolta, N, Marcocci, C, Migliaccio, S, Migliore, A, Muratore, M, Nardi, A, Ortolani, S, Osella, G, Pasquali, R, Petto, H, Pietrogrande, L, Pola, E, Previti, B, Resmini, G, Rubinacci, A, Russo, Pina Elvira, Scillitani, A, Silveri, F, Leali, Pt, Trotta, F, Ulivieri, M, Verdoia, C, Versace, F, and Vinicola, V.

Subjects
Aged, 80 and over, Male, Spinal fracture, Incidence, Osteoporosi, Middle Aged, Parathyroid hormone, Spine, Medication Adherence, Fracture, Observational study, Osteoporosis therapy, Teriparatide, 80 and over, Settore MED/33 - Malattie Apparato Locomotore, Humans, Osteoporosis, Female, Prospective Studies, Aged, Osteoporotic Fractures
Abstract

Objective To estimate the proportion of patients with very severe osteoporosis (those covered by the reimbursement criteria of the Italian National Health Service) experiencing new vertebral and non-vertebral fragility fractures in the first 24 months of a new anti-osteoporosis treatment. Methods Prospective observational study in men and post-menopausal women (aged > 21 years) initiating anti-osteoporosis treatment for very severe osteoporosis. Eligibility was based on teriparatide (TPD) reimbursement criteria in Italy: Incident of vertebral or hip fracture during anti-resorptive treatment (minimum 1 year), or at least three prevalent severe vertebral fractures, or two prevalent severe vertebral fractures and a historical proximal hip fracture. Incidence of new clinical vertebral and non-vertebral fractures was documented by original x-rays and/or radiological reports, and a post-hoc analysis compared data from the TPD monotherapy population versus the total treated group. Results Overall, 767 patients (mean age 72.8 years, 90.7% women) were enrolled in the study, of whom 628, 538, 419 and 424 attended visits at 6, 12, 18 and 24 months, respectively. The most commonly prescribed therapy was TPD (single-agent; 64.5%), then bisphosphonates and other anti-resorptives (33.3%). A combination of different oral treatments was given to 22.5% of the patients. Overall treatment adherence at 24 months was 65.7%. In a post-hoc analysis, the overall incidence of new clinical vertebral and non-vertebral fractures in the total treated population was, respectively, 4.7% and 2.3% in the first 6 months; 1.8% and 1.6% in the 6-12 month period; 2.9% and 1.4% in the 12-18 month period; and 2.2% and 1.0% in the 18-24 month period. Conclusion In patients with very severe osteoporosis, the risk of new vertebral and non-vertebral fractures declined after the first 6 months and remained low throughout the study. Objective To estimate the proportion of patients with very severe osteoporosis (those covered by the reimbursement criteria of the Italian National Health Service) experiencing new vertebral and non-vertebral fragility fractures in the first 24 months of a new anti-osteoporosis treatment. Methods Prospective observational study in men and post-menopausal women (aged > 21 years) initiating anti-osteoporosis treatment for very severe osteoporosis. Eligibility was based on teriparatide (TPD) reimbursement criteria in Italy: Incident of vertebral or hip fracture during anti-resorptive treatment (minimum 1 year), or at least three prevalent severe vertebral fractures, or two prevalent severe vertebral fractures and a historical proximal hip fracture. Incidence of new clinical vertebral and non-vertebral fractures was documented by original x-rays and/or radiological reports, and a post-hoc analysis compared data from the TPD monotherapy population versus the total treated group. Results Overall, 767 patients (mean age 72.8 years, 90.7% women) were enrolled in the study, of whom 628, 538, 419 and 424 attended visits at 6, 12, 18 and 24 months, respectively. The most commonly prescribed therapy was TPD (single-agent; 64.5%), then bisphosphonates and other anti-resorptives (33.3%). A combination of different oral treatments was given to 22.5% of the patients. Overall treatment adherence at 24 months was 65.7%. In a post-hoc analysis, the overall incidence of new clinical vertebral and non-vertebral fractures in the total treated population was, respectively, 4.7% and 2.3% in the first 6 months; 1.8% and 1.6% in the 6-12 month period; 2.9% and 1.4% in the 12-18 month period; and 2.2% and 1.0% in the 18-24 month period. Conclusion In patients with very severe osteoporosis, the risk of new vertebral and non-vertebral fractures declined after the first 6 months and remained low throughout the study.

Published
2016

18. Determinants of Bone Turnover Markers in Healthy Premenopausal Women

Author

Silvano, Adami, Gerolamo, Bianchi, Maria Luisa Brandi, Sandro, Giannini, Sergio, Ortolani, Ombretta, Dimunno, Bruno, Frediani, Maurizio, Rossini, Group Bevilacqua, Bonturno Study M., Bianchi, G., Bosello, O., Cantatore, F., Di Munno, O., Fiore, E., Frediani, B., Frisina, N., Gandolini, G., Giannini, S., Lo Cascio, V., Luisetto, G., Marcocci, C., Minisola, Salvatore, Muratore, M., Nuti, R., Ortolani, S., Rini, G. B., Rossini, M., and Massimo, F.

Subjects
Adult, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, Osteocalcin, Osteoporosis, Reference range, body weight, bone turnover marker, contraceptive pill, normative value, serum phosphate, Bone and Bones, Collagen Type I, Phosphates, Bone remodeling, chemistry.chemical_compound, Endocrinology, Reference Values, Internal medicine, medicine, Humans, Magnesium, Orthopedics and Sports Medicine, Creatinine, biology, business.industry, Confounding, Middle Aged, medicine.disease, Peptide Fragments, Premenopause, chemistry, biology.protein, Calcium, Female, Bone Remodeling, Follicle Stimulating Hormone, Peptides, business, Body mass index, Biomarkers, Procollagen, Hormone
Abstract

Bone turnover markers (BTMs) are widely used for the management of osteoporosis, and the premenopausal reference range is the target value for the treatment of postmenopausal osteoporosis with antiresorbing agents. Three serum BTMs (serum C-telopeptide of type I collagen [CTX], osteocalcin [OC], and N-terminal propeptide of type I procollagen [P1NP]), serum calcium, creatinine, phosphate, magnesium, and follicle-stimulating hormone (FSH) were measured in 638 healthy premenopausal women aged 20-50 years. In 83 women on the contraceptive pill (CP), the levels of the three BTMs adjusted for all confounding factors were 14-26% lower (P0.005) than in non-CP users. In 18 women considered perimenopausal for serum FSH levels30 IU/mL despite having regular menses, BTM levels were significantly higher than in age-matched women. This group of subjects and the women on the CP were excluded from further analysis. The three BTMs significantly decreased with advancing age and were negatively and independently correlated with body mass index (P0.001) and serum phosphate. In conclusion, we confirm that CP use is associated with significantly lower BTM values. An increase in BTM concentrations can be observed in perimenopausal women, i.e., women with normal menses but FSH levels30 IU/mL. BTMs decrease substantially with advancing age, and this appears to be associated with changes in body weight and serum phosphate. New normative ranges for serum OC, CTX, and P1NP were identified; and our findings in general impose a redefinition of the criteria for establishing the normal ranges for BTMs.

Published
2008
Full Text
View/download PDF

20. Improvement of quality of life during treatment with anabolic therapy: results of multicenter study

Author

Minisola, S, Patella, V, Sessa, G, Raso, I, Bevilacqua, M, Fabbri, A, Moretti, B, Cangelosi, AM, Scarpellini, M, Frisina, N, Mancusi, D., LETIZIA MAURO, Giulia, Minisola, S., Patella, V., Sessa, G., Raso, I., Bevilacqua, M., Fabbri, A., Moretti, B., Cangelosi, A., Scarpellini, M., LETIZIA MAURO, G., Frisina, N., and Mancusi, D.

Subjects
Settore MED/34 - Medicina Fisica E Riabilitativa, anabolic therapy, multicenter study, parathyroid hormone
Published
2012

22. Miglioramento della qualità della vita durante il trattamento con terapia anabolica: risultati di uno studio multicentrico

Author

Minisola, S, Patella, V, Sessa, G, Raso, I, Bevilacqua, M, Fabbri, A, Moretti, B, Scarpellini, M, Cangelosi, A. M., Frisina, N, Mancusi, D., LETIZIA MAURO, Giulia, Minisola, S, Patella, V, Sessa, G, Raso, I, Bevilacqua, M, Fabbri, A, Moretti, B, Scarpellini, M, Cangelosi, A.M., Letizia Mauro, G, Frisina, N, and Mancusi, D

Subjects
Settore MED/34 - Medicina Fisica E Riabilitativa, qualità vita, terapia anabolica, studio multicentrico
Published
2011

23. Treatment adherence and QoL with intermittent PTH therapy: Results from a multicentre Italian study after 6 months

Author

Minisola, S., Patella, V., Sessa, G., Raso, I., Bevilacqua, M., Fabbri, A., Moretti, B., Scarpellini, M., Cangelosi, A., Letizia Mauro, G., Frisina, N., Mancusi, D., Minisola, S., Patella, V., Sessa, G., Raso, I., Bevilacqua, M., Fabbri, A., Moretti, B., Scarpellini, M., Cangelosi, A., Letizia Mauro, G., Frisina, N., and Mancusi, D.

Subjects
Settore MED/34 - Medicina Fisica E Riabilitativa, Qol, PTH therapy, osteoporosis, vertebral fractures
Abstract

This ongoing multicentre study was carried out to investigate the adherence to intermittent parathyroid hormone treatment and the effect on QoL in a typical Italian population eligible for drug reimbursement (i.e. a new vertebral or hip fracture following at least one year of anti-resorptive therapy or three severe vertebral fractures or two severe and one femur fracture). 204 female patients (mean age: 72.6±8.3) were enrolled between March 2008 and April 2009. These patients were treated with PTH (PTH 1–34 or PTH 1–84) according to Italian legislation. Here, we report the results obtained at month 6.

Published
2011

24. Baseline characteristics of the population enrolled in the Italian Observational Study on Severe Osteoporosis (ISSO)

Author

Adami S, Maugeri D, Toscano V, Monti S, Vottari S, Topa G, Malavolta N, Buffa A, Brancati A, Massarotti M, Osella G, Iolascon G, Cagnoni C, Camozzi V, Verdoia C, Corradini C, Nardi A, Ulivieri FM, Resmini G, Isaia G, Bevilacqua M, Ortolani S, Pietrogrande L, Rubinacci A, Giannini S, Lo Cascio V, Lacorte R, Massari L, Marcocci C, Di Munno O, Matucci-Cerinic M, Bianchi G, Filipponi P, Mannarino E, Migliaccio S, Spera G, Fornari R, Migliore A, Pola E, Costanzo G, De Marinis L, Di Matteo L, Lombardi G, Altomonte L, Silveri F, Cantatore FP, Scillitani A, Muratore M, Russo E, Salomone S, Barbagallo M, Previti B, Velluti C, Tranquilli Leali P, De Giorgi G, Vinicola V, Vedova D, Frisina N, Stisi S, Gallo A, Bardoscia A, Adami, S, Maugeri, D, Toscano, V, Monti, S, Vottari, S, Topa, G, Malavolta, N, Buffa, A, Brancati, A, Massarotti, M, Osella, G, Iolascon, G, Cagnoni, C, Camozzi, V, Verdoia, C, Corradini, C, Nardi, A, Ulivieri, Fm, Resmini, G, Isaia, G, Bevilacqua, M, Ortolani, S, Pietrogrande, L, Rubinacci, A, Giannini, S, Lo Cascio, V, Lacorte, R, Massari, L, Marcocci, C, Di Munno, O, Matucci-Cerinic, M, Bianchi, G, Filipponi, P, Mannarino, E, Migliaccio, S, Spera, G, Fornari, R, Migliore, A, Pola, E, Costanzo, G, De Marinis, L, Di Matteo, L, Lombardi, G, Altomonte, L, Silveri, F, Cantatore, Fp, Scillitani, A, Muratore, M, Russo, E, Salomone, S, Barbagallo, M, Previti, B, Velluti, C, Tranquilli Leali, P, De Giorgi, G, Vinicola, V, Vedova, D, Frisina, N, Stisi, S, Gallo, A, and Bardoscia, A

Abstract

OBJECTIVES: Baseline characteristics of the population enrolled in the ISSO study, designed to evaluate the incidence of vertebral and non-vertebral fractures in Italian patients with severe osteoporosis treated according to clinical practice over 24 months observation. METHODS: Prospective observational study in 783 post-menopausal women and men entering 18-month treatment with teriparatide in a community setting at 57 centres in Italy. Characterisation included demographics, fracture risk factors, bone mineral density, fracture status, Health-Related Quality of Life (HRQoL) measured by the European Quality of Life Questionnaire, EQ-5D, and back pain assessed by VAS. RESULTS: Most patients were elderly women (90.5%), mean age±SD was 72.9±8.8 years. Nearly all (91.3%) had experienced ≥ 1 vertebral fracture (mean±SD, 3.6±2.2 per patient), 37.5% had ≥ 1 non-vertebral fracture (mean±SD, 1.4±0.7 per patient). Nearly all patients were suffering from back pain (94.9%), which had significantly restricted their daily activities (51.7%) and had likely or very likely been caused by vertebral fractures (29.2% and 55.8%, respectively). Mean EuroQoL EQ-5D index value was 0.58±0.25 and VAS score 49.2±23.6. Non-vertebral fractures, back pain and multiple vertebral fractures were associated with lower HRQoL (EuroQoL-5D Index both p

Published
2011

26. Baseline charateristics of the population enrolled in the Italian Observational Study on Severe Osteoporosis (ISSO)

Author

Adami, S, Maugeri, D, Toscano, V, Topa, G, Carminiti, M, Brancati, A, Massarotti, M, Osella, G, Malavolta, N, Iolascon, G, Cagnoni, C, Camozzi, V, Corradini, C, Nardi, A, Migliaccio, S, Ulivieri, F. M, Resmini, G, Valle, D, Tauchmanovà, L, Silvestri, S, Monti, S, Vottari, S, Buffa, A, Verdoia, C, Ulivieri, Fm, Isaia, G, Bevilacqua, M, Ortolani, S, Pietrogrande, L, Rubinacci, A, Giannini, Sandro, Lo Cascio, V, Lacorte, R, Massari, L, Marcocci, C, Di Munno, O, Matucci Cerinic, M, Bianchi, G, Filipponi, P, Mannarino, E, Spera, G, Fornari, R, Migliore, A, Pola, E, Costanzo, G, De Marinis, L, Di Matteo, L, Lombardi, G, Altomonte, L, Silveri, F, Cantatore, Fp, Scillitani, A, Muratore, M, Russo, E, Salomone, S, Barbagallo, M, Previti, B, Velluti, C, Tranquilli Leali, P, De Giorgi, G, Vinicola, V, Vedova, D, Frisina, N, Stisi, S, Gallo, A, Bardoscia, A., Adami, S, Maugeri, D, Toscano, V, Topa, G, Caminiti, M, Brancati, A, Massarotti, M, Osella, G, Malavolta, N, Iolascon, Giovanni, Cagnoni, C, Camozzi, V, Corradini, C, Nardi, A, Migliaccio, S, Ulivieri, Fm, Resmini, G, Valle, D, Tauchmanova, L, and Silvestri, S.

Subjects
Male, Severity of Illness Index, Cohort Studies, Fractures, Bone, fractures, osteoporosis, treatment, quality of life, observational study, back pain, risk factors, Risk Factors, Teriparatide, 80 and over, severe osteoporosis, Humans, Longitudinal Studies, Prospective Studies, Bone, Aged, Retrospective Studies, Aged, 80 and over, Bone Density Conservation Agents, Incidence, Data Collection, Middle Aged, Italy, Back Pain, Female, Osteoporosis, Quality of Life, Spinal Fractures, Fractures
Abstract

Objective Baseline characteristics of the population enrolled in the ISSO study, designed to evaluate the incidence of vertebral and non-vertebral fractures in Italian patients with severe osteoporosis treated according to clinical practice over 24 months observation. Methods Prospective observational study in 783 post-menopausal women and men entering 18-month treatment with teriparatide in a community setting at 57 centres in Italy. Characterisation included demographics, fracture risk factors, hone mineral density, fracture status, Health-Related Quality of Life (HRQoL) measured by the European Quality of Life Questionnaire, EQ-5D, and back pain assessed by VAS. Results Most patients were elderly women (90.5%), mean age +/- SD was 72.9 +/- 8.8 years. Nearly all (91.3%) had experienced >= 1 vertebral fracture (mean +/- SD, 3.6 +/- 2.2 per patient), 37.5% had >= 1 non-vertebral fracture (mean +/- SD, 1.4 +/- 0.7 per patient). Nearly all patients were suffering from back pain (94.9%), which had significantly restricted their daily activities (51.7%) and had likely or very likely been caused by vertebral fractures (29.2% and 55.8%, respectively). Mean EuroQoL EQ-5D index value was 0.58 +/- 0.25 and VAS score 49.2 +/- 23.6. Non-vertebral fractures, back pain and multiple vertebral fractures were associated with lower HRQoL (EuroQoL-5D Index both p

Published
2011

32. Osteoporosis treatment and fracture incidence: the ICARO longitudinal study

Author

Adami, Silvano, Isaia, G, Luisetto, G, Minisola, S, Sinigaglia, L, Silvestri, S, Agnusdei, D, Gentilella, R, Nuti, R, Albanese, C, Antonelli, M, Aversa, A, Bancheri, C, Barbagallo, M, Bardoscia, A, Bertoni, P, Bianchi, G, Biondi, M, Brandi, Ml, Calitro, M, Cangelosi, R, Cantatore, Fp, Cenci, G, Cianci, A, Coppi, G, DALLE CARBONARE, Luca Giuseppe, D'Amore, M, D'Avola, G, De Candia, R, Del Puente, A, Delvino, Pg, Di Felice, A, Filipponi, P, Fiore, Ce, Francucci, Cm, Frediani, B, Frisina, N, Fruttero, B, Ghirardi, R, Giuntini, D, Giustina, A, Lentini, G, LO CASCIO, Vincenzo, Lucchese, V, Manzara, A, Matina, A, Maugeri, D, Mela, Q, Nardi, A, Occhipinti, R, Osella, G, Perpignano, G, Pisciotta, E, Quattrocchi, G, Rini, G, Rossini, Maurizio, Savoca, S, Silveri, F, and Termini, G.

Subjects
fracture, Osteoporosis, ICARO
Published
2008

33. Erytropoietin: A novel DABA?

Author

Morabito, Nunziata, Gaudio, A, Galati, Em, Pergolizzi, Simona, Taviano, Mf, Lasco, A, Macri', I, Catalano, Antonino, Atteritano, Marco, Occhiuto, Francesco, Corrente, E, Crisafulli, G, and Frisina, N.

Published
2008

34. Un caso di fragilità ossea complicato da plurime fratture vertebrali

Author

Catalano, Antonino, Scamardi, R, Pirrottina, F, Lo Schiavo, G, and Frisina, N.

Subjects
iperomocisteinemia, densità minerale ossea, osteoporosi, rischio di frattura, qualità ossea, teriparatide, teriparatide, rischio di frattura, osteoporosi, iperomocisteinemia, qualità ossea, densità minerale ossea
Published
2008

35. [Therapy with vasopressin receptor antagonists: the aquaretics]

Author

Buemi, M., Bolignano, D., Giuseppe Coppolino, Sturiale, A., Campo, S., Crasci, E., Aloisi, C., and Frisina, N.

Subjects
Heart Failure, Inappropriate ADH Syndrome, urinary osmolarity, plasma sodium, Humans, Aquaretic, vasopressin receptor antagonists, Diuretics, Antidiuretic Hormone Receptor Antagonists, Diuresis, Hyponatremia
Abstract

Aquaretic drugs, by definition, can induce an increase in urinary volume and urinary free water associated with a decreased urinary osmolarity with a consequent increase in plasma sodium. This enhanced diuresis is not accompanied by an increased loss of electrolytes, whereas traditional diuretics have the opposite, so-called saluretic effect. Aquaretics belong to a family of vasopressin receptor antagonists, V2 in particular, that regulate tubular water reabsorption. Several studies have confirmed their utility in the treatment of hyponatremic states associated with water retention such as heart failure, cirrhosis related ascites and SIADH. Furthermore, new applications may include the treatment of arterial hypertension, polycystic kidney disease, glaucoma and Meniere's syndrome.

Published
2007

37. Eritropoietina: un nuovo D.A.B.A.?

Author

Morabito, N, Gaudio, Agostino, Pergolizzi, S, Taviano, Mf, Lasco, A, Macrì, I, Catalano, A, Atteritano, M, Corrente, E, Crisafulli, G, Frisina, N, and Galati, Em

Published
2007

42. Erythropoietin: a novel D.A.B.A.?

Author

Morabito, Nunziata, Gaudio, A, Pergolizzi, Simona, Taviano, Maria Fernanda, Lasco, A, Macrì, I, Catalano, Antonino, Atteritano, Marco, Corrente, E, Crisafulli, G, Frisina, N, and Galati, E. M.

Published
2007

46. Un caso di grave anemia sideropenica

Author

Catalano, Antonino, Atteritano, Marco, Lasco, Antonino, Scamardi, R, and Frisina, N.

Subjects
stenosi valvolare aortica, angiodisplasia, Anemia, emorragia, angiodisplasia, stenosi valvolare aortica, endoscopia digestiva, coagulazione, Anemia, endoscopia digestiva, coagulazione, emorragia
Published
2005

Catalog

Books, media, physical & digital resources
See catalog results